Otsuka and Lundbeck Receive the EC’s Approval for Rxulti to Treat Schizophrenia in Adolescents
Shots:
- The EC has approved Rxulti (brexpiprazole) to treat schizophrenia in pts (≥13yrs.) following CHMP’s positive opinion in Jan 2025
- Approval was based on P-III trial assessing Rxulti (2 to 4mg/day, PO, QD) vs PBO vs Aripiprazole in adolescents (n=316) for 6wks. that showed greater reduction in symptom severity compared to PBO as measured by PANSS total score
- Rxulti modulates serotonin & dopamine systems, combining partial agonist activity at 5-HT1A & D2 receptors with antagonist activity at 5-HT2A receptors. It also antagonizes noradrenergic α1B/2C receptors within the sub-nanomolar Ki range
Ref: Bussineswire | Image: Otsuka and Lundbeck
Related News:- Otsuka’s Lupkynis (voclosporin) Receives NICE Recommendation for the Treatment of Active Lupus Nephritis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
